SCHEMBL8083249

SCHEMBL8083249

NCCCCCNC(=O)CCCCCNC(=O)CCCC[C@@H]1SC[C@@H]2NC(=O)N[C@@H]21

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 5/20 0.74
CA12 O43570 3/20 0.62
CA1 P00915 3/20 0.62
CA2 P00918 3/20 0.62
CA9 Q16790 3/20 0.62
MEN1 O00255 1/20 0.61
ABL1 P00519 1/20 0.61
LMNA P02545 1/20 0.61
PKM P14618 1/20 0.61
IDE P14735 1/20 0.61
MAPK1 P28482 1/20 0.61
KMT2A Q03164 1/20 0.61
RIN1 Q13671 1/20 0.61
L3MBTL1 Q9Y468 1/20 0.61
PLCD1 P51178 1/20 0.60
ITGB1 P05556 1/20 0.57
ITGA4 P13612 1/20 0.57
HLCS P50747 1/20 0.57
F2 P00734 1/20 0.57
PRSS1 P07477 1/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13049579 1.00 TDP1 (0.74) TDP1CA12CA1CA2CA9
SCHEMBL316398 1.00 TDP1 (0.74) TDP1CA12CA1CA2CA9
SCHEMBL10308271 1.00 TDP1 (0.74) TDP1CA12CA1CA2CA9
SCHEMBL13065003 1.00 TDP1 (0.74) TDP1CA12CA1CA2CA9
SCHEMBL9733492 1.00 TDP1 (0.74) TDP1CA12CA1CA2CA9
SCHEMBL288457 1.00 TDP1 (0.74) TDP1CA12CA1CA2CA9
SCHEMBL20375017 1.00 TDP1 (0.74) TDP1CA12CA1CA2CA9
SCHEMBL10140226 1.00 TDP1 (0.74) TDP1CA12CA1CA2CA9
SCHEMBL5437180 1.00 TDP1 (0.74) TDP1CA12CA1CA2CA9
SCHEMBL20483620 1.00 TDP1 (0.74) TDP1CA12CA1CA2CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4646595-A1 PEPTIDE SEQUENCER Oregon Health & Science University (US) 2025-11-12 EP disclosed
WO-2024148174-A1 PEPTIDE SEQUENCER OREGON HEALTH & SCIENCE UNIVERSITY (US) 2024-07-11 WO disclosed
US-20220389478-A1 METHODS TO DETERMINE KDM1A TARGET ENGAGEMENT AND CHEMOPROBES USEFUL THEREFOR ORYZON GENOMICS SA (ES) 2022-12-08 US disclosed
US-20220120739-A1 CHIPS, DETECTORS, AND METHODS OF MAKING AND USING THE SAME SENTILUS HOLDCO, LLC 2022-04-21 US disclosed
US-11169150-B2 Chips, detectors, and methods of making and using the same Sentilus Holdco LLC (US) 2021-11-09 US disclosed
US-11130987-B2 Direct detection of RNA by surface initiated enzymatic polymerization SENTILUS HOLDCO, LLC (US) 2021-09-28 US disclosed
US-11034991-B2 Methods to determine KDM1A target engagement and chemoprobes useful therefor ORYZON GENOMICS S.A. (ES) 2021-06-15 US disclosed
EP-3325966-B1 CHIPS, DETECTORS, AND METHODS OF MAKING AND USING THE SAME Sentilus Holdco LLC (US) 2021-01-20 EP disclosed
US-20190085372-A1 METHODS TO DETERMINE KDM1A TARGET ENGAGEMENT AND CHEMOPROBES USEFUL THEREFOR ORYZON GENOMICS SA (ES) 2019-03-21 US disclosed
EP-3430015-A1 METHODS TO DETERMINE KDM1A TARGET ENGAGEMENT AND CHEMOPROBES USEFUL THEREFOR Oryzon Genomics, S.A. (ES) 2019-01-23 EP disclosed
US-9422602-B2 Methods and compositions for determining nucleic acid degradation BIO-RAD LABORATORIES, INC. (US) 2016-08-23 US disclosed
WO-2015081088-A1 DIRECT DETECTION OF RNA BY SURFACE INITIATED ENZYMATIC POLYMERIZATION IMMUCOR, GTT DIAGNOSTICS, INC. (US) 2015-06-04 WO disclosed
US-20140051595-A1 Methods and Compositions for Determining Nucleic Acid Degradation BIO-RAD LABORATORIES, INC. (US) 2014-02-20 US disclosed
EP-0876385-B1 TOPIRAMATE IMMUNOASSAY, AS WELL AS ANALOGS AND ANTIBODIES OPUS DIAGNOSTICS INC (US) 2000-10-18 EP disclosed
US-6030846-A Homogeneous assays using avidin-binding azo reagents DADE BEHRING INC. (US) 2000-02-29 US disclosed
US-5952187-A ANTIEPILEPTIC AGENT ANALOG DERIVATIZED AT THE SULFAMATE MOIETY OR THE 9-CARBON METHYL GROUP TO ADD LABEL FOR USE IN IMMUNOASSAYS OR TO ADD CARRIER FOR USE AS IMMUNOGEN; FOR MONITORING SERUM OR PLASMA LEVELS OF DRUG OXIS INTERNATIONAL, INC. (US) 1999-09-14 US disclosed
EP-0876385-A1 TOPIRAMATE IMMUNOASSAY, AS WELL AS ANALOGS AND ANTIBODIES Oxis International, Inc. (US) 1998-11-11 EP disclosed
WO-1997019950-A1 TOPIRAMATE IMMUNOASSAY, AS WELL AS ANALOGS AND ANTIBODIES OXIS INTERNATIONAL, INC. (US) 1997-06-05 WO disclosed
US-5612221-A Avidin-binding fluorescing and quenching reagent for use in homogeneous assays DADE CHEMISTRY SYSTEMS INC. (US) 1997-03-18 US disclosed
US-5536820-A Avidin-binding azo reagents E. I. DU PONT DE NEMOURS AND COMPANY (US) 1996-07-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220389478-A1 METHODS TO DETERMINE KDM1A TARGET ENGAGEMENT AND CHEMOPROBES USEFUL THEREFOR KDM1B, KDM1A, KDM7A TDP1 1918/4885CA12 2752/4885CA1 1658/4885
US-20190085372-A1 METHODS TO DETERMINE KDM1A TARGET ENGAGEMENT AND CHEMOPROBES USEFUL THEREFOR KDM1B, KDM1A, KDM7A TDP1 1918/4885CA12 2752/4885CA1 1658/4885
US-11034991-B2 Methods to determine KDM1A target engagement and chemoprobes useful therefor KDM1B, KDM1A, KDM7A TDP1 1918/4885CA12 2752/4885CA1 1658/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.